… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a … its clinical stage pipeline programs and the Axiomer ® RNAediting platform. ProQR leadership will highlight key …
… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … Medicines Symposium on June 29, 2022 as part of the RNAEditing track. The Company’s presentation will be webcast …
… company dedicated to changing lives through transformative RNA therapies, today announced several presentations … highlighting the Company’s proprietary Axiomer ® RNAediting technology platform at upcoming scientific and …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNAediting technology platform, today reported its financial …
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that … RNA therapies for genetic eye diseases and our proprietary RNA-editing platform technology.” “I first met Daniel more than a …
AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and trial design details to be announced in H2 2024$4.5 million in milestones
